PARP inhibitors in gastric cancer: beacon of hope

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Defects in DNA damage response (DDR) lead to genomic instability, promoting cancer development and progression.
• Poly (ADP-ribose) polymerase (PARP) is crucial for DNA repair, replication, and transcription, initiating poly (ADP-ribosylation) (PARylation) upon DNA single-strand breaks (SSB).
• PARP and associated proteins regulate DNA repair through PARylation, offering therapeutic targets.

Purpose of the Study:

• To review the antitumor mechanisms of PARP inhibitors (PARPis).
• To summarize the preclinical and clinical advancements of PARPis in gastric cancer (GC).
• To explore PARPis as both monotherapy and combination therapy for GC.

Main Methods:

• Review of scientific literature on PARP inhibitors and their role in DNA damage repair.
• Analysis of preclinical data regarding PARPis efficacy in various cancer models.
• Examination of clinical trial results for PARPis in gastric cancer patients.

Main Results:

• PARP inhibitors block SSB repair, creating synthetic lethality in homologous recombination deficiency (HRD) cancers.
• PARPis demonstrate antitumor activity as monotherapy and in combination regimens.
• Significant preclinical and clinical progress has been made in evaluating PARPis for gastric cancer.

Conclusions:

• PARP inhibition is a viable anticancer strategy, particularly for HRD-positive cancers like GC.
• Further clinical investigation of PARPis in GC is warranted to optimize therapeutic outcomes.
• PARPis represent a promising avenue for novel gastric cancer treatments.